Is age limiting factor for nivolumab treatment?
MUDr. Libor Havel
Pneumologická klinika, Thomayerova nemocnice, Praha
Immunotherapy as a new treatment modality is currently widely accepted and perceived as a modality in NSCLC treatment, which is changing the prognosis of patients in the long term. But it is not entirely clear how immunotherapy is suitable for patients of advanced age.
immunotherapy, nivolumab, NSCLC, elderly patients
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...